SCNI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Scinai Immunotherapeutics Ltd · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.27 USD
18.7% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -52.9% below the Trend Line and sits at 3.3% of its 52-week range. The latest completed week returned 18.7%, after a 1.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 38d.

Setup score 13 out of 100
Latest Close 0.27 USD 31 Jul 2026
1W Return 18.7% latest completed week
4W Return 1.0% short-term follow-through
12W Return -51.9% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 18.7% Latest completed week; four-week move 1.0%. Indicator stack 0/35 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 38.57% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 49/100 52 relevant articles in the latest sentiment read. Event risk 38d Next report is scheduled for 09 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -52.9% below the Trend Line and sits at 3.3% of its 52-week range. The latest completed week returned 18.7%, after a 1.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0012-week average 0.01

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 1.0% over four weeks, -51.9% over 12 weeks, and -81.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W18.7%
4W1.0%
12W-51.9%
26W-72.1%
52W-81.4%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.90Latest activity-pressure read.
Pressure change12.7%Four-week change in activity pressure.
Leadership-72.02Latest relative-leadership reading.
RS change6.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength38/100Blend of value, momentum, and quality. Underlying universe rank 63; rank 1 is best.
Value44/100Relative valuation strength. Underlying universe rank 57; rank 1 is best.
Quality43/100Profitability and accounting quality. Underlying universe rank 58; rank 1 is best.
Momentum45/100Medium-term price momentum. Underlying universe rank 56; rank 1 is best.
Growth45/100Revenue and earnings growth. Underlying universe rank 56; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-83.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-202.3%
Gross profit retained from each unit of revenue.
Operating margin
-606.3%
Operating profit retained from revenue.
Free-cash-flow margin
-458.2%
Free cash flow generated from revenue.
Return on invested capital
-49.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment49/100

Weighted news tone is neutral across 52 relevant articles.

8 positive · 36 neutral · 8 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings38dNext report is scheduled for 09 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-86.1%Distance below the 52-week high.
13-week volatility11.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher4 of 2622 weeks finished lower.
Best week+32.8%Week of 24 Apr.
Worst week-21.9%Week of 26 Jun.
Latest week+18.7%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains0
Flat weeks0
Modest losses8
Sharp losses14
Recent vol11.0%13-week weekly-return volatility.
Base vol12.3%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew8.9% / -9.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape14/100

Trend, activity pressure, participation, and risk combine to a 14/100 tape read.

 Indicator analysis21/100

Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.

Activity pressure 0.00; No reversal markers Next-Week ExpectancyNegative 38.57%

Next-week expectancy is negative with a 38.57% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors41/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment49/100

Weighted news tone is neutral across 52 relevant articles.

Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates Insiders50/100

No recent insider transaction evidence is stored.

 Earnings38d

Next report is scheduled for 09 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.27 USD18.7%0.58 USD3.39 USD-0.90-72.02842.8KOff
24 Jul 20260.23 USD-7.9%0.59 USD3.47 USD-0.92-77.00377.9KOff
17 Jul 20260.25 USD-0.4%0.61 USD3.56 USD-1.00-76.459.6MOff
10 Jul 20260.25 USD-7.3%0.63 USD3.65 USD-1.04-78.30368.1KOff
3 Jul 20260.27 USD7.7%0.66 USD3.74 USD-1.03-77.23356.5KOff
26 Jun 20260.25 USD-21.9%0.69 USD3.83 USD-1.00-79.531.2MOff
19 Jun 20260.32 USD-2.9%0.72 USD3.92 USD-0.79-75.984.6MOff
12 Jun 20260.33 USD-19.7%0.74 USD4.00 USD-0.59-75.592.3MOff
5 Jun 20260.41 USD-8.4%0.76 USD4.09 USD-0.30-70.052.1MOff
29 May 20260.45 USD-2.4%0.78 USD4.17 USD-0.03-70.03961.9KOff
22 May 20260.46 USD-14.0%0.81 USD4.28 USD0.28-69.731.5MOff
15 May 20260.54 USD-5.6%0.84 USD4.39 USD0.66-65.86735.5KOff
8 May 20260.57 USD-20.0%0.87 USD4.51 USD0.56-65.42886.7KOff
1 May 20260.71 USD-3.7%0.90 USD4.63 USD0.55-56.034.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.